ID: ALA4095928

Max Phase: Preclinical

Molecular Formula: C27H28ClN5O2S

Molecular Weight: 522.07

Molecule Type: Small molecule

Representations

Canonical SMILES:  C/C(N)=N\C(=N/S(=O)(=O)c1ccc(C(C)C)cc1)N1CC(c2ccccc2)C(c2ccc(Cl)cc2)=N1

Standard InChI:  InChI=1S/C27H28ClN5O2S/c1-18(2)20-11-15-24(16-12-20)36(34,35)32-27(30-19(3)29)33-17-25(21-7-5-4-6-8-21)26(31-33)22-9-13-23(28)14-10-22/h4-16,18,25H,17H2,1-3H3,(H2,29,30,32)

Standard InChI Key:  PLCVQFDHZUZAMO-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 522.07

Molecular Weight (Monoisotopic): 521.1652

AlogP: 5.39

#Rotatable Bonds: 5

Polar Surface Area: 100.48

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 7.85

CX LogP: 5.14

CX LogD: 4.57

Aromatic Rings: 3

Heavy Atoms: 36

QED Weighted: 0.36

Np Likeness Score: -0.82

References

1. Iyer MR, Cinar R, Katz A, Gao M, Erdelyi K, Jourdan T, Coffey NJ, Pacher P, Kunos G..  (2017)  Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB1R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis.,  60  (3): [PMID:28085283] [10.1021/acs.jmedchem.6b01504]

Source

Source(1):

• Scientific Literature